BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AIBioTech Executive VP to Present Largest Pharmacogenomic Study to Date at IONWorld2013


10/15/2013 10:25:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Richmond, VA—AIBioTech Co-Founder and Executive Vice President Thomas Reynolds will present the results of a novel multiplex pharmacogenomics panel and accompanying data at the IONWorld2013 conference October 21, in Boston, Massachusetts.

Reynolds will present AIBioTech’s process for developing its multiplex Personalized Medicine Panel as well as genotyping frequencies on all genes in AIBioTech’s panel for more than ten thousand de-identified clinical specimens. His presentation will also compare AIBioTech’s large pool of clinical data to published genotype frequencies from smaller studies in four different ethnic populations: African-American, Caucasian, Hispanic, and Asian.

“The data generated from this study will provide new insights into the ethnic frequency of CYP enzyme mutations that affect drug dosing and management,” said Reynolds.

AIBioTech’s Personalized Medicine Panel utilizes Next Generation sequencing technology on the Ion Torrent Personal Genome Machine™ to analyze ten genetic markers associated with the Cytochrome P450 (CYP) enzymes that metabolize many commonly prescribed drugs and cardiac risk factors Factor II (prothrombin), Factor V Leiden, and MTHFR.

The panel categorizes patients into one of four metabolizer categories for each of the enzyme markers and provides actionable information for physicians regarding dosing and possible negative drug interactions. AIBioTech has processed more than twenty thousand patient samples on this platform to date, a unique milestone for any laboratory utilizing the ION Torrent technology.

About AIBioTech® (American International Biotechnology Services, LLC)

AIBioTech is a unique combination of diagnostic laboratory and comprehensive contract research organization. Based on over 20 years of experience with DNA sequencing, assay development and practical research applications, AIBioTech provides clinical testing services and research and development services to physicians and life science investigators in clinical practices; biotechnology and pharmaceutical companies; academic institutions and in several different government agencies For more information about its capabilities and services visit the company website at www.aibiotech.com.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

AIBioTech
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES